Company intelligence / Profile preview
三元基因
北京, 北京, 中国triprime.com ↗
- Ownership
- Private
- Employees
- ~262
- Development stage
- Other
01
Overview
Tri‑Prime Gene’s lead product, recombinant human interferon α1b, is China’s first gene-engineered class I new drug with independent IP rights and is approved for the treatment of various viral diseases and some cancers. The company has multiple clinical-stage projects and more than ten new drug certificates.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Recombinant proteinBiologicCell therapy
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on 三元基因.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 三元基因.